Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Equivalence: In Vitro and In Vivo Bioequivalence01:17

Equivalence: In Vitro and In Vivo Bioequivalence

163
Body:Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts.
163
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

850
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
850
Biological Methods for Microbial Control01:28

Biological Methods for Microbial Control

720
Biological agents offer an effective means of controlling microbial growth by leveraging natural processes like predation, competition, and the secretion of antimicrobial substances.Predatory bacteria such as Bdellovibrio species target and kill pathogens like Salmonella and E. coli. They are widely used in poultry farms to control infections. Myxococcus species help combat plant-pathogenic fungi. These naturally occurring predators serve as eco-friendly alternatives to chemical pesticides and...
720

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Laboratory testing and standardisation.

Haemophilia : the official journal of the World Federation of Hemophilia·2013
Same author

Standards and monitoring treatment.

Haemophilia : the official journal of the World Federation of Hemophilia·2012
Same author

History of heparin.

Handbook of experimental pharmacology·2012
Same author

Insights from factor IX activation studies with chromogenic assays: implications of disparate product results.

Haemophilia : the official journal of the World Federation of Hemophilia·2010
Same author

Effects of apoptosis and lipid peroxidation on T-lymphoblastoid phospholipid-dependent procoagulant activity.

Journal of thrombosis and haemostasis : JTH·2008
Same author

A collaborative study to establish the 1st International Standard for factor XIII plasma.

Journal of thrombosis and haemostasis : JTH·2007

Related Experiment Video

Updated: Dec 28, 2025

Monitoring Influenza Virus Survival Outside the Host Using Real-Time Cell Analysis
09:02

Monitoring Influenza Virus Survival Outside the Host Using Real-Time Cell Analysis

Published on: February 20, 2021

3.4K

Viral inactivation vs biological activity

T W Barrowcliffe1

  • 1National Institute for Biological Standards and Control, Potters Bar, Herts., UK.

Developments in Biological Standardization
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Viral inactivation of blood products like factor concentrates poses challenges. These methods can alter protein function, increase immunogenicity, and cause thrombotic events, impacting patient safety.

More Related Videos

Alternative In Vitro Methods for the Determination of Viral Capsid Structural Integrity
12:57

Alternative In Vitro Methods for the Determination of Viral Capsid Structural Integrity

Published on: November 16, 2017

8.6K
Assays for the Identification of Novel Antivirals against Bluetongue Virus
12:02

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

14.4K

Related Experiment Videos

Last Updated: Dec 28, 2025

Monitoring Influenza Virus Survival Outside the Host Using Real-Time Cell Analysis
09:02

Monitoring Influenza Virus Survival Outside the Host Using Real-Time Cell Analysis

Published on: February 20, 2021

3.4K
Alternative In Vitro Methods for the Determination of Viral Capsid Structural Integrity
12:57

Alternative In Vitro Methods for the Determination of Viral Capsid Structural Integrity

Published on: November 16, 2017

8.6K
Assays for the Identification of Novel Antivirals against Bluetongue Virus
12:02

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

14.4K

Area of Science:

  • Biotechnology and Pharmaceutical Sciences
  • Hematology and Transfusion Medicine

Background:

  • Viral inactivation of blood products is crucial for safety but technically challenging.
  • Coagulation factor concentrates are complex mixtures requiring preservation of biological function.
  • Existing methods like dry heat, solvent/detergent, and pasteurization have limitations.

Purpose of the Study:

  • To evaluate the impact of viral inactivation techniques on coagulation factor concentrates.
  • To assess the preservation of biological functions and potential adverse effects.
  • To understand changes in protein integrity and immunogenicity.

Main Methods:

  • Analysis of factor VIII (FVIII) and factor IX (FIX) concentrates treated with viral inactivation methods.
  • Assessment of FVIII activation markers (potency assays, FXa generation, polypeptide analysis).
  • Evaluation of thrombogenicity in FIX concentrates and impact on coagulation inhibitors.

Main Results:

  • Viral inactivation methods can lead to FVIII activation, evidenced by altered potency and increased degradation products.
  • A switch to pasteurization for FVIII concentrates correlated with increased FVIII antibody incidence in hemophilic patients.
  • Viral inactivation processes may induce immunosuppressive changes and increase thrombotic potential in FIX concentrates.

Conclusions:

  • Current viral inactivation techniques for blood products present significant challenges.
  • These methods can compromise protein integrity, increase immunogenicity, and introduce safety concerns like thrombogenicity.
  • Further research is needed to optimize viral inactivation while maintaining the safety and efficacy of blood products.